Smoldering Myeloma

Treatments

We help myeloma patients find, understand and connect with their eligible clinical trial options from around the US. Create your account today to start your personalized clinical trial report.

Create My Account

Did you know...

There are nearly 100 treatments in active development for multiple myeloma around the US. We can help you understand your options for clinical trials, compassionate use as well as standard of care therapies.

Call us today and we can help answer any questions that you may have. You can also create your free account to get your personalized report.

Call or text us today

(888) 828-2206

Create My Account

Treatments

All Treatments

View all treatments in development for myeloma patients around the US.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Iopofosine I-131 (CLR 131)
Iopofosine I-131 (CLR 131)

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen) Pepaxto®

Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

Verified Selinexor
Selinexor Xpovio®

is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma. 

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Iopofosine I-131 (CLR 131)
Iopofosine I-131 (CLR 131)

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen) Pepaxto®

Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified Selinexor
Selinexor Xpovio®

is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma. 

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Iopofosine I-131 (CLR 131)
Iopofosine I-131 (CLR 131)

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen) Pepaxto®

Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

Verified Mezagitamab
Mezagitamab

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

Verified Selinexor
Selinexor Xpovio®

is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma. 

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).